← All organizations
Highest phase reached
Phase 3
First clinical trial
Dec 1, 2012Last known activity
Oct 31, 2023
Timeline
2000s
- Jan 1, 2009
Cellular Biomedicine Group Ltd.— Founded
Drugs by trial phase (16 distinct, 28 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Phase 1 (7 own, 0 via acquisition)
Other trials (2 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Alzheimer Disease
- Carcinoma
- Carcinoma, Hepatocellular
- Coronavirus Infections
- Infections
- Leukemia
- Leukemia, Lymphoid
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Osteoarthritis
- Osteoarthritis, Knee
- Pneumonia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Prostatic Neoplasms
- Respiratory Aspiration
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Stomach Neoplasms
- Syndrome
Recent trials (28)
- NCT05996224Lead sponsorPhase 3Oct 31, 2023
- NCT05800977Lead sponsorPhase 1/Phase 2Feb 22, 2023
- NCT05521802Lead sponsorPhase 1/Phase 2Aug 31, 2022
- NCT05421663Lead sponsorPhase 1Aug 9, 2022
- NCT05475847CollaboratorPhase 1Jul 31, 2022
- NCT05632380CollaboratorPhase 1/Phase 2Jul 14, 2022
- NCT04602104CollaboratorPhase 1/Phase 2Oct 31, 2020
- NCT04544215CollaboratorPhase 1/Phase 2Jul 1, 2020
- NCT04388982CollaboratorPhase 1/Phase 2May 25, 2020
- NCT04313647CollaboratorPhase 1Mar 16, 2020
- NCT04276987CollaboratorPhase 1Feb 15, 2020
- NCT04208646Lead sponsorPhase 2Dec 31, 2019
- NCT04295018CollaboratorPhase 1Oct 23, 2019
- NCT03971747Lead sponsorPhase 1Jun 30, 2019
- NCT04036019CollaboratorPhase 1May 13, 2019
Details
- Founded
- Palo Alto, US Jan 1, 2009
- Last known activity
- Oct 31, 2023